Information was received from a health care professional (hcp) via a device manufacturer representative regarding a patient receiving dilaudid (8000 mcg/ml at 3000 mcg/day) via an implantable infusion pump.
It was reported that the patient came in for a refill on (b)(6) 2021.
Later that day, they experienced drowsiness, labored breathing and cyanotic skin color.
They were admitted to the intensive care unit (icu) and given narcan.
They withdrew the medication from the pump and got 18mls, but expected 20mls.
The doctor suspected overdose and subsequently decreased the infusion rate on (b)(6) 2021.
The patient's pain control was not adequate after reducing the infusion rate, so he was prescribed oral supplemental opioids on (b)(6) 2021.
The hcp made the decision to replace the pump due to suspected overinfusion.
Upon explant, 6.
5mls were expected but the actual residual volume was 3.
5mls.
The backflow of cerebrospinal fluid was sluggish.
A back table prime was conducted on the new pump prior to attaching to the existing catheter, and infusion was started at 2550 mcg/day without priming the catheter.
The issue was considered resolved.
The patient's status at the time of the report was alive - no injury.
No further complications were reported.
|